自动化病灶追踪在[68Ga]Ga-PSMA-11 PET/CT中实现高精度疗效分类并保留预后价值
本研究在132例生化复发前列腺癌患者的配对[68Ga]Ga-PSMA-11 PET/CT中验证自动化病灶追踪算法,其病灶匹配准确率达95.1%,患者层面RECIP 1.0、PPP和TLW分类准确率分别为95.5%、96.2%和96.2%,且各框架下进展性疾病均与总生存期显著相关。
要点
- 自动化病灶追踪算法病灶匹配准确率达95.1%,错配与配准质量较差相关。
- 算法衍生的RECIP 1.0、PPP和TLW分类与专家参考高度一致,准确率均超95%。
- 三种框架下进展性疾病均保持对总生存期的预后意义。
核心结论
- 自动化病灶追踪算法以高准确率复现专家匹配,并在生化复发队列中保留RECIP 1.0、PPP和TLW的预后效用,支持其作为PSMA PET/CT定量疗效评估的可重复病灶匹配方法。
研究设计与样本
- 研究纳入132例生化复发前列腺癌患者的配对基线与随访[68Ga]Ga-PSMA-11 PET/CT扫描,使用基于配准的流水线自动进行一对一病灶对应,将病灶标记为对应、消失或新发,并与专家参考标签比较。
- 算法衍生的RECIP 1.0、PPP和TLW分类与专家参考标签比较,并使用单变量Cox回归检验其与总生存期的关联。
主要发现
- 共识别1,066个病灶(基线559个,随访507个),包括371个对应病灶、188个消失病灶和136个新发病灶,产生695个匹配决策。
- 病灶匹配算法达到95.1%的匹配准确率,病灶错配与较差的配准质量相关。
- 算法衍生的患者层面疗效分类与真实框架高度一致,RECIP 1.0分类准确率为95.5%,PPP为96.2%,TLW为96.2%。
- 所有框架均保留对总生存期的预后意义,进展性疾病的风险比为:RECIP 1.0 HR=2.57(95%CI 1.33-4.98),PPP HR=2.02(95%CI 1.04-3.90),TLW HR=2.29(95%CI 1.22-4.28)。
关键数值与推荐
- 病灶匹配准确率95.1%;患者层面分类准确率:RECIP 1.0为95.5%,PPP为96.2%,TLW为96.2%。
- 进展性疾病对总生存期的风险比:RECIP 1.0 HR=2.57(95%CI 1.33-4.98),PPP HR=2.02(95%CI 1.04-3.90),TLW HR=2.29(95%CI 1.22-4.28)。
临床怎么用
- 该算法可作为可重复的病灶匹配工具,用于PSMA PET/CT定量疗效评估,辅助RECIP 1.0、PPP和TLW框架的自动化分类。
- 配准质量较差时需警惕病灶错配,可能影响分类准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to validate an automated lesion-tracking algorithm for [68Ga]Ga-PSMA-11 PET/CT against expert reference matches and to evaluate its integration into three PSMA-specific treatment response frameworks-the Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0), PSMA PET Progression (PPP) criteria, and the Traffic Light Workflow (TLW)-in men with biochemically recurrent (BCR) prostate cancer (PCa). METHODS: Paired baseline and follow-up [68 Ga]Ga-PSMA-11 PET/CT scans from 132 BCR PCa patients were analysed using a registration-based pipeline that automatically assigned one-to-one lesion correspondences. Lesions were labelled as corresponding (CL), disappearing (DL) or new (NL). Algorithm-derived RECIP 1.0, PPP, and TLW categories were compared with expert reference labels and tested for overall survival (OS) association using univariable Cox regression. RESULTS: A total of 1,066 lesions were identified (559 baseline, 507 follow-up), including 371 CLs, 188 DLs, and 136 NLs, yielding 695 matching decisions. The lesion matching algorithm achieved 95.1% matching accuracy. Lesion mismatches were associated with poorer registration quality. Algorithm-derived patient-level response classifications showed high concordance with ground-truth frameworks, with classification accuracy of 95.5% for RECIP 1.0, 96.2% for PPP, and 96.2% for TLW. All frameworks retained prognostic significance for OS, with progressive disease conferring hazard ratios (HR) of-RECIP 1.0 HR = 2.57 (95% CI 1.33-4.98), PPP HR = 2.02 (95% CI 1.04-3.90), and TLW HR = 2.29 (95% CI 1.22-4.28). CONCLUSION: The automated lesion-tracking algorithm reproduced expert matches with high accuracy and preserved the prognostic utility of RECIP 1.0, PPP, and TLW in a BCR cohort, supporting its use as a reproducible lesion-matching method for quantitative response assessment on PSMA PET/CT. TRIAL REGISTRATION NUMBER: ACTRN ACTRN12615000608561. Registered 11 June 2015. Retrospectively registered.
引用
- Lucas T, Dell'Oro M, Ong JSL, et al. Automated lesion tracking and treatment response classification on [68Ga]Ga-PSMA-11 PET/CT across PPP, RECIP 1.0 and TLW frameworks. Eur J Nucl Med Mol Imaging. 2026. PMID: 42461410. doi:10.1007/s00259-026-08071-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。